Research location
Barcelona
Catalonia, Spain
Advertisement
Research activity in Barcelona
Catalonia, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 374 trials and 516 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Barcelona
374 linked trials · page 3 of 8A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast CancerNCT05346224 · 2022-04-25 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)NCT05267470 · 2022-03-29 · 2 site observations
TERMINATED
Characterization of Type 2 Diabetes Subgroups at Diagnosis: a Necessary Step Towards Precision Medicine in Diabetes.NCT05333718 · 2022-03-08 · 2 site observations
UNKNOWN
Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsNCT04772235 · 2022-02-11 · 1 site observation
UNKNOWN
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line TreatmentNCT04933695 · 2022-01-28 · 2 site observations
TERMINATED
Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.NCT05181462 · 2022-01-11 · 2 site observations
COMPLETED
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNCT05054725 · 2021-12-30 · 1 site observation
COMPLETED
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)NCT05156281 · 2021-12-13 · 1 site observation
ACTIVE_NOT_RECRUITING
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)NCT05060016 · 2021-12-01 · 3 site observations
ACTIVE_NOT_RECRUITING
A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035)NCT05093933 · 2021-11-02 · 1 site observation
COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 in BCRNCT04838613 · 2021-09-30 · 1 site observation
COMPLETED
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)NCT05017012 · 2021-09-21 · 1 site observation
COMPLETED
Integral Cognitive Remediation for DepressionNCT07014683 · 2021-09-19 · 1 site observation
COMPLETED
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors DetectionNCT04838626 · 2021-09-07 · 1 site observation
COMPLETED
Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast CancerNCT04874025 · 2021-07-31 · 3 site observations
COMPLETED
Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With IntentNCT04722666 · 2021-07-20 · 1 site observation
TERMINATED
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).NCT04895722 · 2021-06-25 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)NCT04895358 · 2021-06-18 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of AMG 757 in Participants With Neuroendocrine Prostate CancerNCT04702737 · 2021-06-10 · 1 site observation
COMPLETED
Effect of Dapagliflozin in Myocardial Fibrosis and Ventricular Function in Patients With a ST-segment Elevation Myocardial InfarctionNCT06619600 · 2021-05-30 · 2 site observations
UNKNOWN
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)NCT04700072 · 2021-05-03 · 1 site observation
COMPLETED
Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)NCT04725188 · 2021-04-20 · 2 site observations
COMPLETED
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 1 site observation
ACTIVE_NOT_RECRUITING
Insomnia in the Patient With Schizophrenic Disorder: Evaluation of a CBT and Psychoeducational InterventionNCT05115604 · 2021-04-08 · 1 site observation
COMPLETED
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLCNCT04681131 · 2021-03-17 · 3 site observations
COMPLETED
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)NCT04623775 · 2021-02-17 · 1 site observation
COMPLETED
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's DiseaseNCT04592874 · 2021-01-22 · 1 site observation
COMPLETED
Develop a Multi-disciplinary Approach for a Personalized Prenatal Diagnostics and Care for Twin PregnanciesNCT04595214 · 2020-12-21 · 1 site observation
UNKNOWN
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)NCT04626518 · 2020-12-17 · 1 site observation
COMPLETED
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)NCT04626479 · 2020-12-16 · 1 site observation
COMPLETED
Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer SurvivorsNCT05401643 · 2020-11-01 · 1 site observation
COMPLETED
Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual MalesNCT04055142 · 2020-09-18 · 1 site observation
COMPLETED
Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping MutationsNCT04323436 · 2020-08-19 · 1 site observation
TERMINATED
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)NCT04428151 · 2020-08-06 · 1 site observation
COMPLETED
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)NCT04305054 · 2020-07-01 · 1 site observation
COMPLETED
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.NCT04285866 · 2020-05-21 · 1 site observation
COMPLETED
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell TransplantNCT03774082 · 2020-05-20 · 1 site observation
COMPLETED
Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsNCT04223596 · 2020-05-04 · 1 site observation
ACTIVE_NOT_RECRUITING
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)NCT04233216 · 2020-03-18 · 1 site observation
COMPLETED
Registry of Asthma Patients Initiating DUPIXENT®NCT04287621 · 2020-03-02 · 3 site observations
COMPLETED
Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)NCT04233879 · 2020-02-28 · 2 site observations
COMPLETED
A Phase I/Ib Study of NIZ985 Alone and in Combination With SpartalizumabNCT04261439 · 2020-02-27 · 1 site observation
TERMINATED
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast CancerNCT03937154 · 2020-02-26 · 1 site observation
ACTIVE_NOT_RECRUITING
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid TumorsNCT04278144 · 2020-02-24 · 2 site observations
TERMINATED
Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%NCT04139317 · 2020-01-22 · 1 site observation
TERMINATED
Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.NCT04253145 · 2019-12-13 · 1 site observation
UNKNOWN
Clinical Evaluation of CEM-guided BiopsyNCT05250674 · 2019-10-08 · 1 site observation
COMPLETED
Multimodal Prehabilitation in Thoracic SurgeryNCT04052100 · 2019-10-01 · 1 site observation
UNKNOWN
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesNCT04000529 · 2019-07-30 · 1 site observation
TERMINATED
ATL001 in Patients With Advanced Unresectable or Metastatic NSCLCNCT04032847 · 2019-07-08 · 1 site observation
TERMINATED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.